آخر تحديث :
19/11/2024
Infostab
قائمة المركبات
ملخص القوائم
ابحث عن التوافق
جدول توافق موقع ص
مراجع
فرق البحث
valistab
الملصق
الروابط
الرعاة
الكتاب
دليل المستخدم
النشرة الإخبارية
Doxorubicin hydrochloride
التركيب الكيميائي
حجز الاسم التجاري
تحذير الأسماء التجاريه المختلفه قد تحتوي علي محتوي إضافات مختلفة حسب الدوله و المعمل
Adriacept
ألمانيا
Adriamycin
أستراليا, الدنمارك, النرويج, النمسا, الولايات المتحدة, فنلندا, كندا
Adriblastin
النمسا, سويسرا
Adriblastina
إيطاليا, البرازيل, بلجيكا, بولندا, تركيا, سلوفينيا, كرواتيا, يونان
Adriblastine
فرنسا, يونان
Adrimedac
ألمانيا
Biorub
البرازيل
Biorubina
بولندا
Dicladox
الأرجنتين
Doxolem
البرازيل
Doxorubicine
سويسرا, فرنسا
Doxorubin
بلجيكا, يونان
Farmiblastina
إسبانيا
Rastocin
بولندا
Robodoxo
ألمانيا
مراجع : Doxorubicin hydrochloride
نوع
منشور
3
مجلة
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26
مجلة
Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
32
مجلة
Nyhammar EK, Johansson SG, Seiving BE.
Stability of doxorubicin and vincristine sulfate in two portable infusion-pump reservoirs.
Am J Health-Syst Pharm 1996 ; 53: 1171-1173.
57
مجلة
Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81
مجلة
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84
مجلة
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85
مجلة
Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91
مجلة
Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99
مجلة
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
142
مجلة
Rochard EB, Barthes DMC, Courtois PY.
Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs.
Am J Hosp Pharm 1992 ; 49: 619-623.
148
مجلة
Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I.
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Pharm Weekbl [Sci] 1992 ; 14: 365-369.
150
مجلة
Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
167
مجلة
Francomb MM, Ford JL, Lee MG.
Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters.
Int J Pharm 1994 ; 103: 87-92.
169
مجلة
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
184
مجلة
Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244
مجلة
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249
مجلة
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
300
مجلة
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301
مجلة
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307
مجلة
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334
مجلة
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335
مجلة
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
408
مجلة
Beijnen JH, Neef C, Meuwissen OJAT, Rutten JJMH, Rosing H, Underberg WJM.
Stability of intravenous admixtures of doxorubicin and vincristine.
Am J Hosp Pharm 1986 ; 43: 3022-3027.
492
مجلة
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
632
مجلة
Beijnen JH, Rosing H, De Vries PA, Underberg WJM.
Stability of anthracycline antitumour agents in infusion fluids.
J Parenter Sci Technol 1985 ; 39: 220-222.
660
مجلة
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
681
مجلة
Walker S, Lau D, DeAngelis C, Iazetta J, Coons C.
Doxorubicin stability in syringes and glass vials and evaluation of chemical contamination.
Can J Hosp Pharm 1991 ; 44: 71-78.
686
مجلة
Wood MJ, Irwin WJ, Scott DK.
Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags.
J Clin Pharm Ther 1990 ; 15: 279-289.
740
مجلة
Hoffman DM, Grossano DD, Damin LA, Woodcock TM.
Stability of refrigerated and frozen solutions of doxorubicin hydrochloride.
Am J Hosp Pharm 1979 ; 36: 1536-1538.
763
مجلة
Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326.
847
مجلة
Tavoloni N, Guarino AM, Berck PD.
Photolytic degradation of adriamycin.
J Pharm Pharmacol 1980 ; 32: 860-862.
859
مجلة
Karlsen J, Thonnesen HH, Olsen IR, Sollien AH, Skobba TJ.
Stability of cytotoxic intravenous solutions subjected to freeze-thaw treatment.
Nor Pharm Acta 1983 ; 45: 61-67.
905
مجلة
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921
مجلة
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026
مجلة
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033
مجلة
Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 1999 ; 56: 985-989.
1160
مجلة
Beijnen JH, van der Houwen OAGJ, Underberg WJM.
Aspects of the degradation kinetics of doxorubicin in aqueous solution.
Int J Pharm 1986 ; 32: 123-131.
1237
مجلة
Keusters L, Stolk LML, Umans R, Van Asten P.
Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation.
Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265
مجلة
Wood MJ, Irwin WJ, Scott DK.
Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography.
J Clin Pharm Ther 1990 ; 15: 291-300.
1284
مجلة
Williams BA, Tritton TR.
Photoinactivation of anthracyclines.
Photochem Photobiol 1981 ; 34: 131-134.
1286
مجلة
Trissel LA, Xu QA, Gilbert DL.
Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions.
Ann Pharmacotherapy 1998 ; 32: 1013-1016.
1408
مجلة
Priston MJ, Sewell GJ.
Stability of three cytotoxic drugs infusions in the Graseby 9000 ambulatory infusion pump.
J Oncol Pharm Practice 1998 ; 4: 143-149.
1410
مجلة
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415
مجلة
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423
مجلة
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496
مجلة
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1520
مختبر
Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1606
مجلة
Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625
مجلة
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662
مجلة
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1897
مجلة
Sautou-Miranda V, Brigas F, Thibault M, Chopineau J.
Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage.
EJHP 2001 ; 7, 3: 108-115.
1925
مجلة
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953
مجلة
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1955
مجلة
Trissel LA, Zhang Y.
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Ann Pharmacotherapy 2005 ; 39: 280-283.
1982
مجلة
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2094
مجلة
Trittler R.
Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS.
EJHP Science 2006 ; 12, 1: 10-12.
2247
مجلة
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2256
مختبر
Stability of doxorubicin "Ebewe" infusion solutions.
Ebewe Pharma 2007
2262
مجلة
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128
مختبر
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3402
مجلة
Hecq, J.-D., Lewis, A.L., Vanbeckbergen, D., Athanosopoulos, A., Galanti, L., Jamart, J., Czuczman, P., Chung, T.
Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: A stability assessment.
J Oncol Pharm Practice 2013 ; 19, 1: 65-74.
3474
مختبر
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3531
مختبر
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3540
مختبر
Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3574
مختبر
Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3645
مختبر
Doxorubicin - Summary of Product Characteristics
Accord Healthcare 2014
3668
مختبر
Dexamethasone - Summary of Product Characteristics
Hospira 2015
3670
مجلة
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3706
مجلة
Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B.
Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia.
Farm Hosp 2014 ;38, 3:154-161
4102
مجلة
Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y.
Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care.
J Oncol Pharm Practice 2018 ;25,4:831-840.
4471
مختبر
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019
Mentions Légales